Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Reuters

07/17

Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552485955"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552485955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552485955?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552485955","market":"us","top_or_hot":-1,"title":"Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harrow Inc., a prominent <a href=\"https://laohu8.com/S/FNCSF\">North American</a> eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-17 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harrow Inc., a prominent <a href=\"https://laohu8.com/S/FNCSF\">North American</a> eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL9dtc3g:1","article_id":"2552485955","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552485955","pubTimestamp":1752750045,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ and OPUVIZ, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","HROW":"Harrow Health Inc","BK4007":"制药"},"translate_title":"Harrow Inc.拥有三星Bioepis眼科生物仿制药的独家权利，扩大在美国的业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    \n\n        Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}